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Abstract
Rationale
Perioperative myocardial ischemia is common in high-risk patients. The use of interven-
tional revascularisation or even thrombolysis is limited in this patient subset due to exceed-
ingly high bleeding risks. Blockade of voltage-gated sodium channels (VGSC) with
lidocaine had been suggested to reduce infarct size and cardiomyocyte cell death in ische-
mia/reperfusion models. However, the impact of lidocaine on cardiac function during sus-
tained ischemia still remains unclear.
Methods
Sustained myocardial ischemia was induced by ligation of the left anterior descending
artery in 12–16 weeks old male BALB/c mice. Subcutaneous lidocaine (30 mg/kg) was
used to block VGSC. Cardiac function was quantified at baseline and at 72h by conven-
tional and speckle-tracking based echocardiography to allow high-sensitivity in vivo pheno-
typing. Infarct size and cardiomyocyte cell death were assessed post mortem histologically
and indirectly using troponin measurements.
Results
Ischemia strongly impaired both, global systolic and diastolic function, which were partially
rescued in lidocaine treated in mice. No differences regarding infarct size and cardiomyo-
cyte cell death were observed. Mechanistically, and as shown with speckle-tracking analy-
sis, lidocaine specifically improves residual contractility in the ischemic but not in the
remote, non-ischemic myocardium.
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Conclusion
VGSC blockade with lidocaine rescues function of ischemic myocardium as a potential
bridging to revascularisation in the setting of perioperative myocardial ischemia.
Introduction
Outcome of acute myocardial ischemia remarkably improved with the availability of interven-
tional and pharmacological revascularisation techniques. Unanticipated myocardial ischemia
in the perioperative phase however is frequent in high-risk patients and substantially affects
morbidity and mortality [1]. Unfortunately, percutaneous coronary intervention with subse-
quent need for dual anti-platelet therapy or pharmacological thrombolysis carries an exceed-
ingly high bleeding risk in this patient subset.
Myocardial ischemia leads to accumulation of intracellular sodium (Na+i) and, through
mechanisms including the sacrolemmal Na+/Ca++ exchanger and other pathways, an increase
in intracellular calcium (Ca++i). This accumulation of Ca
++
i during ischemia is deleterious as it
results in increased diastolic wall tension, myocardial contractile work and oxygen consump-
tion [2,3]. The compression of the vascular space during diastole reduces remaining coronary
and myocardial blood flow, resulting in a viscious circle of increased myocardial oxygen
demand and decreased oxygen supply.
Na+ can enter the cell through voltage-gated sodium channels (VGSC). This not only occurs
when VGSC are opened during the upstroke of the action potential, but also through persistent
Na+ current. Under normal conditions, persistent Na+ current represents a small fraction of
the peak gradient only. However, it is greatly enhanced under hypoxic conditions and is
thought to largely contribute to the increase in Na+i during ischemia [4–6].
Previous studies have demonstrated that lidocaine, a local anesthetic and class Ib antiarrhyth-
mic that blocks VGSC, reduces Na+i and prevents Ca
++-overload in myocardial ischemia [7].
Conversely, application of lidocaine during myocardial ischemia was demonstrated to improve
functional parameters such as cardiac contractility in highly artificial experimental settings of
explanted and perfused Langendorff-hearts, or of static parameters such as histological infarct
size in very short term in vivomodels[7–9]. Moreover, data derived from in vitro studies on iso-
lated cardiomyocytes suggest a possible impact of VGSC blockade on diastolic cardiac function
[10]. However, the relevance of these observations in the more complex pathophysiological
response that occurs during, and within the first days after myocardial ischemia remains unclear.
We hypothesized that administration of lidocaine might lessen the deterioration of cardiac
function in sustained myocardial ischemia, allowing to bridge the time until revascularisation
can be performed with a reasonable risk for bleedings. To keep the influence on cardiovascular
function as small as possible, we used in vivo phenotyping with high-perfomance echocardiog-
raphy techniques requiring only minimal anesthesia.
Methods
Experimental Myocardial Infarction
All animal procedures were approved by the institutional Animal Care and Use Committee of
the University of Zurich, Switzerland and were in accordance with swiss federal law. Twelve to
sixteen weeks old and weight matched BALB/c mice were obtained from the local breeding
facility and housed in a temperature-controlled environment on an alternating 12h light/dark
cycle.
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Myocardial infarction was induced by ligation of the left anterior descending artery (LAD)
as described before[11]. Briefly, mice were intubated with a 20 gauge polypropylene tube after
induction of anesthesia (4% isoflurane) and ventilated with a small animal volume-control ven-
tilator (Harvard Apparatus, Holliston, MA) at tidal volumes of 280 μl and 120 cycles per min-
ute. Anesthesia was maintained with 2% of isoflurane. The thoracic cavity was opened by left-
sided thoracotomy and the heart exposed. The LAD was visualized and ligated with an 8–0
suture just distal of its appereance under the left atrial appendage. This induces a well repro-
ducible and large area of ischemic myocardium that is easily distinguishable macroscopically
from the non-ischemic myocardium. The thoracic cavity and skin were then closed with 4–0
suture and the animal was extubated after restoration of spontaneous respiration. Sham oper-
ated mice (n = 8) underwent the same procedure, with the exception that the 8–0 suture was
not tightened. All animals received analgesia with 2 mg/kg bodyweight flunixin meglumine in
12h intervalls. Postoperatively, all animals were checked twice daily for specified signs of stress
and pain (spontaneous activity, posture, mouse grimace scale and weight). Animals were
euthanized using 10 minutes of insufflation with carbon dioxide when meeting pre-specified
criteria or the 72h endpoint following echocardiography. A detailed outline of these criteria
can be found in S1 File. Mortality in the first 72h (including mice that were euthanized accord-
ing to the prespecified criteria) following LAD ligation was 35%, which is expected in this
model [12–14]. An outline of the experimental protocol can be found in S1 Fig.
Echocardiography
Echocardiography was performed using a digital small animal ultrasound system (Vevo 2100
Imaging System, VisualSonics, Toronto, Canada) with a 18 to 38 Mhz linear-array probe[15].
Animals were lightly sedated with isoflurane and placed on a heating pad. To keep the influence
of anesthesia on cardiovascular physiology during echocardiography as small as possible, all mice
were anesthesized with a constant of 2% of isoflurane applied via a face mask, maintaining heart
rates of>400 bpm. The complete aquisition of all images required approximately 8 minutes per
mouse. All examinations were performed by a single investigator (EO) blinded for the experi-
mental groups. Standardized two-dimensional long- and short axis views as well as apical
4-chamber views were obtained from all animals to assess LV size and function. Left ventricular
ejection fraction (EF) was calculated as ([end-diastolic volume—end-systolic volume]/end-dia-
stolic volume) x 100. Left ventricular fractional area change (FAC) was calculated as ([end-dia-
stolic area—end-systolic area)/end-diastolic area) x 100. Longitudinal strain (LS) was calculated
as the change of length of a specific segment divided by its original length ([L1-L0]/L0).
Pulsed-wave Doppler was used in the apical 4-chamber view to measure early (E) and late
(A) mitral inflow velocities. Early (Ea) and late (Aa) mitral valve velocities were quantified by
tissue Doppler imaging. Due to the in our experience insufficient image quality in the apical
4-chamber views in mice following thoracotomy, tissue Doppler was performed in the para-
sternal short-axis view on the level of the chordae tendineae as described before[16].
Analysis of all images was performed offline by two (BME, EO) independent, blinded inves-
tigators for the conventional measurements and by one (BME) blinded investigator for the
semi-automated strain measurements using the Vevo2100 Software Version 1.6. The inter-
observer-variability was low with an intra-class-correlation coefficient for EF and FAC of 0.93
and 0.92, respectively.
Randomization and Experimental Protocol
Animals were randomized to the control or treatment group prior to the baseline echocardiog-
raphy using a free online randomizer (www.randomizer.org). Animals of the treatment group
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received a total of six doses of 30mg/kg bodyweight of lidocaine (lidocaine hydrochloride,
10mg/ml, Sintetica, Mendisio, Switzerland). We chose the subcutaneous route to allow for a
sustained drug effect and decreased toxicity. The reported LD50 of subcutaneous lidocaine in
mice is 200–400 mg/kg (summary report 1999, committee for veterinary medicinal products,
EMEA). Animals were injected in 12h intervals, starting 30 minutes following LAD ligation.
Animals of the control group received an equal volume of phosphate-buffered saline in the
before mentioned interval.
Troponin Measurements
Blood was harvested by puncture of the inferior vena cava. Troponin T was quantified using
the Elecysy Troponin T high sensitive system (Roche, Basel, Switzerland). The detection limit
of this assay is 3 pg/ml.
Histological Quantification of Infarct Size
Hearts were fixed in 4% formaldehyde, cut into three transverse slices of equal size (basal,
mid ventricular and apical level) parallel to the atrioventricular groove as described before
[15] and embedded in paraffin. For Masson-Trichrome staining, slides were deparaffinized
in 70% ethanol, followed by incubation steps in iron-hematoxylin, ponceau xylidine/fuch-
sin acid/azophloxin and phosphotungstic acid hydrate-Orange-G followed by counter-
staining with waterblue, with several washing steps using acetic acid or distilled water in
between.
Total LV endocardial circumference and the endocardial circumference occupied by scar
tissue staining positive for Masson-Trichrome at the basal, mid ventricular and apical level was
analysed in a semi-automatic fashion by a blinded investigator using imageJ (Bethesda, MD).
Infarct size was then calculated as the mean percentage of endocardial circumference occupied
by the scar tissue of the LV.
Statistical Analysis
Mortality between mice of the control and treatment group was compared using the Log-rank
test. Data was checked for normality using Kolmogorov-Smirnow-test. Normally distributed
data were analysed using t-test (two groups) or One-way-ANOVA with Holm-Sidak posthoc
test (> two groups).
Non-normally distributed data was compared using the Kruskal-Wallis-test with Dunn
posthoc test (> 2 groups) or Mann-Whitney-test (2 groups).
Intraclass-correlation to compare the interobserver agreement of the two independent echo
analysts was calculated for absolute agreement in two-way mixed mode. Hotelling T-Test was
used in the analysis of mitral flow velocities.
A p< 0.05 was considered significant. Statistical calculations were carried out using either
SPSS Statistics Version 22 (IBM, Armonk, NY) or Graphpad Prism Version 6 (Graphpad Soft-
ware, La Jolla, CA).
Results
Preoperative Characteristics and Echocardiographic Validation of
Myocardial Ischemia Model
Preoperative descriptive and baseline echocardiographic values did not differ between animals
that were randomized to the treatment or control group (Table 1).
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Ligation of the LAD resulted in an average histological infarct size 72h following ligation of
45.3% of the left ventricular circumference, which is in line with reported results for this model
[8,15]. Mortality within the first 72h following LAD ligation was 35%, comparable to what oth-
ers report[12–14]. No difference was observed between mice of the control and lidocaine
group (S2 Fig; p = 0.77).
Global systolic LV function in terms of EF, FAC as well as speckle-tracking based measure-
ments of LS was drastically impaired with LS demonstrating the strongest percentage change
(S3A and S3B Fig)[15]. Regional analysis showed that functional impairment is limited to
ischemic LV segments of the infarct zone (S3C and S3D Fig). Mice developed diastolic dysfunc-
tion with a restrictive filling pattern (S4A and S4B Fig).
Lidocaine treatment rescues global systolic and diastolic LV function
LAD ligation led to a deterioration of global LV systolic function. Functional impairment, how-
ever, was reduced in lidocaine-treated mice (Fig 1A, p = 0.0184 for EF, p = 0.0343 for FAC).
This effect was also evident using speckle tracking analysis with improved LS in mice receiving
lidocaine (Fig 1B, p = 0.0198 for LS).
Table 1. Descriptive preoperative values of control and treatment mice.
Control lido
n = 8 n = 8
body weight (g) 30,56 (0,78) 31,03 (0,53) n.s.
heart rate (bpm) 413 (9,58) 435 (11,31) n.s.
EF (%) 56,18 (0,38) 54,0,6 (0,99) n.s.
FAC (%) 38,36 (0,69( 36,62 (0,76) n.s.
EDV* (ml) 71,61 (3,32) 66,23 (2,04) n.s.
area* (sq mm) 27,66 (0,53) 26,74 (0,81) n.s.
LS (%) -10,935 (0,466) -8,94 (0,92) n.s.
*measured at end- diastole
n.s. non-signiﬁcant
EF ejection fraction, FAC fractional area change, EDV end-diastolic volume, LS longitudinal strain
doi:10.1371/journal.pone.0154699.t001
Fig 1. Lidocaine treatment rescues global systolic function during ischemia. Absolute values of conventional echocardiographic parameters
EF and FAC (A) and speckle-tracking derived LS (B) before (white bars) and 72h following LAD ligation (black bars) with lidocaine or vehicle are
given. EF, FAC and LS are partially rescued with lidocaine (*p = 0.0184 for EF; *p = 0.0343 for FAC; *p = 0.0198 for LS). EF ejection fraction, FAC
fractional area change, LS longitudinal strain.
doi:10.1371/journal.pone.0154699.g001
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The development of restrictive filling and diastolic dysfunction with LAD ligation as evi-
denced by a strong increase in the E/A and Ea/Aa ratios was blunted with lidocaine (Fig 2A
and 2B).
Lidocaine Treatment Does Not Affect Cardiomyocyte Necrosis and
Infarct Size
Serum troponin as a marker of cardiomyocyte necrosis was demonstrated to correlate to infarct
size[17]. Accordingly, we found strong increases of serum troponin levels following LAD liga-
tion. There was, however, no difference between control and lidocaine treated animals (Fig
3A). In line with these findings, histological infarct size was comparable in mice of the control
and the lidocaine group (Fig 3B and 3C).
Lidocaine Rescues Contractility of the Ischemic Region
As infarct sizes did not differ between the control and lidocaine group, regional systolic func-
tion was investigated by speckle tracking. Only LV segments of the ischemic region demon-
strated improved residual contractility with lidocaine treatment (p = 0.0167). In contrast, no
effect of lidocaine was demonstrated in non-ischemic, viable regions (Fig 4). In line with these
findings, there was no effect of lidocaine on global LV function in sham operated animals that
were not subjected to myocardial ischemia (S5 Fig).
Discussion
Perioperative myocardial ischemia remains a clinical challenge as an exceedingly high bleeding
risk limits the use of pharmacological lysis therapy or interventional revascularisation in these
patients. Targeting the intracellular sodium homeostasis during ischemia was reported to be
beneficial in ex vivo- or short-term in vivo-models focusing on histological parameters of car-
diac injury[7,8,18]. We here provide for the first time functional in vivo data, which
Fig 2. Lidocaine treatment attenuates diastolic dysfunction during ischemia. A + B Ratios of mitral
inflow velocities (E/A) and mitral valve anulus velocities (Ea/Aa) are preserved following LAD ligation in mice
receiving lidocaine (gray bars) as compared to mice receiving vehicle instead (black bars) and are
comparable to preoperative values (white bars). p* = 0.0078, p**<0.0001.
doi:10.1371/journal.pone.0154699.g002
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demonstrate that blockade of voltage-gated sodium channels with lidocaine attenuates deterio-
ration of global heart function by improving the residual contractility in ischemic regions of
the heart.
Fig 3. Lidocaine does not affect cardiomyocyte cell death. A High-sensitivity (hs)-Troponin T is equally
elevated 72h following LAD ligation in mice receiving lidocaine (lido) or vehicle (control). B Infarct size given
as percentage circumference of the left ventricle that is infarcted is comparable in mice receiving lidocaine
and in control animals.C Representative slides from the mid-ventricular section of hearts 3 days following
LAD ligation and stained with masson-trichrome. n.d. not detectable; LV left ventricle.
doi:10.1371/journal.pone.0154699.g003
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Previous work on the effect of sodium channel blockade during myocardial ischemia was
limited to ex vivo studies using isolated and perfused hearts[7,18], or to experiments, which
addressed myocardial tissue damage or serum markers of cardiomyocyte cell death [8,19].
In our study, we addressed for the first time the functional impact of lidocaine treatment on
cardiac function in an in vivomodel of myocardial infarction. We took advantage of the most
recent small-animal echocardiography techniques that allow detailed phenotyping of global
and regional heart function, while limiting physiological alterations due to prolonged sedation,
as needed for cardiac magnetic resonance imaging, to a minimum[15]. We found that LAD
ligation leads to a vast decrease in conventional echocardiographic parameters of global systolic
left ventricular function (EF and FAC) within 72h, which was even more pronounced using
novel speckle tracking (LS). This confirms findings from Bauer et al., who also report a higher
sensitivity for alterations of systolic myocardial function using speckle tracking[15].
Subcutaneous application of lidocaine twice daily rescued global systolic function in our
model. The beneficial effect was evident in conventional echocardiographic measurements as
well as in speckle tracking analysis of LS.
Significant systolic dysfunction is often associated with an impaired left ventricular filling
during diastole. We found that LAD ligation leads to a strong decrease in late mitral inflow (A)
and late mitral valve velocity (Aa) and consecutively increase in the E/A- and Ea/Aa ratios as
signs of impaired diastolic function[20,21]. Treatment with lidocaine partially rescued diastolic
function. While a clinical disease entity of diastolic heart failure with preserved systolic func-
tion as well as a respective animal models exists[20], diastolic dysfunction in our model occurs
in conjunction with a sudden drop in systolic function. Our current data therefore does not dif-
ferentiate whether the effect of VGSC blockade with lidocaine on diastolic function is merely a
consequence of an improved systolic function in these mice or independent of this. However,
inhibition of persistent sodium current had been demonstrated to decrease LV diastolic
Fig 4. Lidocaine improves residual function of ischemicmyocardium. Regional LS of segments of the
infarcted region (MA, AA, AI) and the non-ischemic, remote region (BI, MI) are shown. Treatment with
lidocaine results in improved LS following LAD ligation in the infarcted region (gray bars) as compared to mice
receiving vehicle (black bars), while no effect of lidocaine is apparent in the remote region. LS longitudinal
strain,MAmid-anterior, AA apical-anterior, AI apical-inferior, BI basal-inferior,MI mid-inferior; *p = 0.0167.
doi:10.1371/journal.pone.0154699.g004
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pressure [22–24], making it likely that the observed effects on diastolic function in our model
are, at least partially, mediated by a direct effect of VGSC blockade with lidocaine.
Lidocaine had been suggested to reduce both infarct size and the release of troponins as
serum markers of cardiomyocyte cell death in animal models of myocardial ischemia and
reperfusion[8]. Kaczmarek et al. further observed that in the same experimental setup, applica-
tion of lidocaine only during reperfusion was sufficient to reproduce the tissue-protective
effect. The beneficial mechanisms of VGSC blockade with lidocaine that lead to a reduction of
infarct size and troponin release during myocardial ischemia and reperfusion therefore seem to
be most important during the phase of reperfusion. In line with these findings, we were unable
to detect differences in either infarct size or troponins in our model of sustained myocardial
ischemia.
Kaczmarek et al. further reported that reductions in infarct size and troponin release were
due to a decrease in cardiomyocyte apoptosis in the lidocaine group. Previous findings demon-
strated that cardiomyocyte cell death differs between ischemia and reperfusion: while cell
death during ischemia is thought to be mainly due to necrosis[25], restoration of blood flow
allows to fulfill cellular energy needs required for completion of apoptosis, hence accelerating
cell death during reperfusion[26]. In our model, lidocaine did not alter cell death and infarct
size which might be related to a predominant necrotic cell death due to sustained ischemia.
The mode of delivery of lidocaine might also contribute to the observed differences, as Kacz-
marek et al used a continuous infusion during their short-term model as compared to subcuta-
neous injection in 12h-intervalls in the current study. While osmotic micropumps for use in
mice that would allow a continuous release over several days are now available, simultaneous
LAD ligation and implantation of such pump would significantly increase the burden on the
animals and presumably mortality.
Volatile anesthetics such as isoflurane that was used in the current study are well known for
their cardioprotective properties in tissue ischemia when applied before the ischemic event
(preconditioning)[27]. We used isoflurane for anesthesia during LAD ligation, during postop-
erative echocardiography 72h after LAD ligation and during baseline echocardiography that
was performed 48h before LAD ligation. To keep the influence of anesthesia as small as possi-
ble, isoflurane was strictly kept at 2% at all time points and in all study groups. However, we
cannot exclude that the initial exposure to isoflurane during baseline echocardiography might
have already reduced ischemic cardiac tissue damage resulting in no apparent effect on infarct
size with further protection with lidocaine.
We observed differences in global systolic and diastolic function although infarct sizes were
comparable in both, control and treatment groups. Analysis of regional wall motion of non-
ischemic segments of the left ventricle by speckle tracking showed unaltered function with lido-
caine treatment. However, segments of the ischemic region demonstrated improved residual
contractility with lidocaine treatment, accounting for improved overall cardiac function. Block-
ade of VGSC was demonstrated before to decrease diastolic LV pressure ex vivo [22–24]. In
line, we found preserved diastolic function in lidocaine-treated mice. Ischemic myocardium is
particularly vulnerable to diastolic dysfunction, as the associated increase in wall tension com-
presses the vascular bed and reduces remaining coronary and myocardial blood flow during
diastole. This effect might account for the observed improved contractility that is pronounced
in the ischemic regions. Consistently, lidocaine did not affect cardiac function in the non-ische-
mic heart of sham-operated animals.
Voltage-gated sodium channels are involved in the rapid depolarisation during the phase 0
of the action potential and VGSC-blocking drugs can therefore affect impulse propagation.
While class Ib antiarrhythmics such as lidocaine have in general only little proarrhythmic
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effects, we cannot exclude fatal arrhythmias in mice of our treatment group as continuous
ECG-monitoring was not available in our animal facility.
In summary, we extend previous studies by demonstrating that blockade of VGSC with
lidocaine improves global LV systolic and diastolic function in myocardial ischemia in vivo by
sustaining residual contractility of the ischemic myocardium. Lidocaine treatment might there-
fore be beneficial as a bridging therapy to revascularisation in perioperative myocardial ische-
mia until revascularisation can be performed with a tolerable risk for bleeding.
Supporting Information
S1 File. Animal care and severity score sheet.
(PDF)
S1 Fig. Experimental protocol.
(TIF)
S2 Fig. Survival analysis. Kaplan-Meier curves are shown for postoperative survival in control
(solid line) and lidocaine-treated mice (dashed line) during the observation period of 72h. The
survival curves are compared using the log rank test (p = 0.77).
(TIF)
S3 Fig. Echocardiographic validation of myocardial ischemia model. 12 to 16 weeks old
BALB/c mice were subject to LAD ligation via left-sided thoracotomy. Echocardiography was
performed before ligation (white bars) and 72h postoperative (black bars). A LAD ligation lead
to a strong decrease in conventional echocardiographic parameters of EF (p<0.0001) and
FAC (p<0.0001), as well as speckle-tracking measurement of LS (p<0.0001). B Percentage
change following LAD ligation was higher for speckle-tracking derived LS than for conven-
tional measurement of of EF (= 0.0432), but not FAC (p>0.05). C + D Regional quantification
of LS revealed the most pronounced change in segments of the infarcted region (mid-anterior
[MA], apical-anterior [AA] and apical-inferior [AI]) as compared to remote, non-ischemic
segments (basal-inferior [BI], mid-inferior [MI]) p<0.05, p<0.001 in C; p = 0.0002 in D.
EF ejection fraction, FAC fractional area change, LS longitudinal strain, BA basal-anterior,MA
mid-anterior, AA apical-anterior, AI apical-inferior,MI mid-inferior, BI basal-inferior.
(TIF)
S4 Fig. Diastolic function in myocardial ischemia. A Early (E) and late (A) mitral inflow
velocites and E/A ratio are given. LAD ligation leads to a drop in late mitral inflow velocity
(p<0.0001) and consecutive rise in E/A (p = 0.0037). B Early (Ea) and late (Aa) mitral valve
anulus velocities and Ea/Aa ratio are given. As shown for mitral inflow velocities, mitral valve
anulus late velocity (Aa) drops following LAD ligation (p = 0.008) with a consecutive rise in
Ea/Aa ratio (p = 0.0023). White bars show preoperative values, black bars show values 3 days
postoperative.
(TIF)
S5 Fig. Lidocaine does not affect systolic function in non-ischemic hearts. Percentage
changes to preoperative values 3 days following sham operation in animals without and with
lidocaine treatment are shown. EF ejection fraction; FAC fractional area change
(TIF)
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